CompletedPhase 1NCT05541861

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
BioNTech SE
Principal Investigator
BioNTech Responsible Person
BioNTech SE
Intervention
BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg(biological)
Enrollment
383 target
Eligibility
18 years · All sexes
Timeline
20222024

Study locations (17)

Collaborators

Pfizer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05541861 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials